SCHEMBL526322

SCHEMBL526322

C[C@H](Cc1cc(C#N)c2c(c1)CCN2CCCO)NCCOc1ccccc1OCC(F)(F)F

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 20/20 0.75
ADRA1A P35348 20/20 0.75
ADRA1B P35368 20/20 0.75
ADRB2 P07550 1/20 0.75
HTR1A P08908 1/20 0.75
ADRA2A P08913 1/20 0.75
DRD2 P14416 1/20 0.75
ADRA2B P18089 1/20 0.75
ADRA2C P18825 1/20 0.75
DRD1 P21728 1/20 0.75
DRD4 P21917 1/20 0.75
PTGS1 P23219 1/20 0.75
HTR1D P28221 1/20 0.75
HTR1B P28222 1/20 0.75
HTR7 P34969 1/20 0.75
HRH1 P35367 1/20 0.75
OPRM1 P35372 1/20 0.75
DRD3 P35462 1/20 0.75
HTR2B P41595 1/20 0.75
SLC6A3 Q01959 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13730436 1.00 ADRA1D (0.75) ADRA1DADRA1AADRA1BADRB2HTR1A
Hydrochloric Acid SCHEMBL13736802 0.99 ADRA1D (0.74) ADRA1DADRA1AADRA1BADRB2HTR1A
Hydrochloric Acid SCHEMBL13731163 0.99 ADRA1D (0.74) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL13037437 0.93 ADRA1D (0.65) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL18306489 0.92 ADRA1D (0.63) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL1822919 0.91 ADRA1D (0.62) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL6709958 0.91 ADRA1D (0.65) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL10064164 0.91 ADRA1D (0.75) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL6709954 0.91 ADRA1D (0.65) ADRA1DADRA1AADRA1BADRB2HTR1A
SCHEMBL28996811 0.91 ADRA1D (0.66) ADRA1DADRA1AADRA1BADRB2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180339964-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINESALT BIOCON LIMITED (IN) 2018-11-29 US claimed
EP-3353149-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINE SALT Biocon Limited (IN) 2018-08-01 EP claimed
WO-2017051324-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINE SALT BIOCON LIMITED (IN) 2017-03-30 WO claimed
WO-2012147107-A2 NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION MSN LABORATORIES LIMITED (IN) 2012-11-01 WO claimed
EP-1806340-B1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME KISSEI PHARMACEUTICAL (JP) 2011-05-04 EP claimed
US-7834193-B2 Indoline compound and process for producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US claimed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US claimed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP claimed
US-10377710-B2 Process for the preparation of considerably pure Silodosin MANKIND PHARMA LTD. (IN) 2019-08-13 US disclosed
US-20180339964-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINESALT BIOCON LIMITED (IN) 2018-11-29 US disclosed
EP-3353149-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINE SALT Biocon Limited (IN) 2018-08-01 EP disclosed
WO-2018100565-A1 PROCESS FOR THE PREPARATION OF INDOLINE COMPOUND GRANULES INDIA LIMITED (IN) 2018-06-07 WO disclosed
US-9932308-B2 Method for producing indoline compound UBE INDUSTRIES, LTD. (JP) 2018-04-03 US disclosed
US-9932308-B2 Method for producing indoline compound UBE INDUSTRIES, LTD. (JP) 2018-04-03 US disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
WO-2006046499-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339964-A1 THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINESALT BPHL, QPCT, DAO ADRA1D 113/4885ADRA1A 609/4885ADRA1B 787/4885
US-10377710-B2 Process for the preparation of considerably pure Silodosin CYP51A1, LSS, SRI ADRA1D 378/4885ADRA1A 646/4885ADRA1B 557/4885
US-20070197627-A1 Indoline compound and process for producting the same BPHL, DAO, INHA ADRA1D 369/4885ADRA1A 1628/4885ADRA1B 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.